Monoclonal antibody based biomarker discovery and development platform
US8512959B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 9, 2005 |
| Grant date | Aug 20, 2013 |
| Priority date | — |
| Expiry date | Jun 9, 2028 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/00
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A method or platform for monoclonal antibody based biomarker discovery is disclosed. The method according to the invention provides for the integration of analyte collection, hybridoma screening and nanovolume integrated mass spectrometry (NVIMS) to achieve a robust screening system that is capable, for example, of cutting 4-6 years off of the classical biomarker discovery and development process. The invention provides a platform for the rapid, high-throughput production, isolation and characterization of, e.g., disease specific biomarkers together with highly specific monoclonal antibodies. The method of the invention has a variety of applications such as, but not limited to, drug testing, biohazard applications, ecological applications, physiological applications and/or pathology screening applications. The method of the invention is also capable of being performed or used as or with a high-throughput screening process or system of the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.